Anthos Therapeutics Announces Abelacimab Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with AFib
Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Source: dicardiology.com